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very year, more than 10 million people are diag-
nosed with cancer. Over half of them live in the de-
veloping world, where the cancer incidence rate has 
reached pandemic proportions. In 2008 there were upward 
of 12.4 million estimated new cases of cancer, with approx-
imately two–thirds of the estimated 7 .6 million cancer 
deaths occurring in low–and middle–income countries [1]. 
Although low– and middle–income countries bear the ma-
jority of the disease burden, their health systems are inad-
equately prepared to address the challenge of care. Since 
cancer kills more people worldwide than HIV/AIDS, tuber-
culosis, and malaria combined, it needs to be a global 
health priority.
Low– and middle–income countries bear the greatest bur-
den of new cancer cases as well as deaths, amid an ever–
increasing total number of affected individuals worldwide. 
In 2012 an estimated 14 million new cases were reported, 
with this figure anticipated to rise to 22 million over the 
next twenty years [1]. Significantly, more than 60% of the 
world’s total cancer cases occur in Africa, Asia, Central 
America, and South America, while greater than 70% of 
the world’s cancer deaths come from these same regions 
[2]. By 2030 the developing world is expected to account 
for 70% of newly reported cancer cases. What is more, sur-
vival rates are meager in poor countries and on the rise in 
wealthy ones [3]. For a wide range of cancers, an individ-
ual’s likelihood of surviving is closely and positively related 
to country income (Figure 1 and 2).
Part of the reason why low– and middle–income countries 
lag behind wealthy nations in cancer survival rates is a lack 
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of awareness, prevention, and early detection, as well as 
inaccessibility of new and more effective treatments that 
have been developed in recent decades and made available 
to many in the first world. Greater than 30% of cancer–re-
lated deaths in the developing world are estimated to be 
preventable [2]. Thus, in the case of low– and middle–in-
come countries, the demand for cancer prevention and 
treatment services is far from being met. With burgeoning 
survival rates among those suffering from AIDS and other 
diseases in low– and middle–income countries the preva-
lence of cancer will only increase, thereby resulting in an 
even greater need for cancer services in these areas.
While significant attention and financial support has re-
sulted in expanded access to treatment for AIDS and other 
infectious diseases over the past decade, cancer is a concern 
that remains relegated to the periphery of the global health 
community. Despite its prevalence throughout the devel-
oping world cancer is conspicuously absent from central 
global health programs, including the United Nations Mil-
lennium Development Goals [4].
Cancer is a leading cause of mortality in low– and middle–
income countries, equaling over five million annually. Dis-
proportionate access to prevention and treatment, in addi-
Every year, more than 10 million people are di-
agnosed with cancer. Over half of them live in 
the developing world, where the cancer inci-
dence rate has reached pandemic proportions.V
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tion to an ageing and growing population and decreasing 
mortality rates resulting from infectious diseases, will cause 
new cancer cases and cancer mortality to continue to rise 
in coming years. The global health community must take 
decisive action to bridge the cancer divide between wealthy 
and poor nations. Such action should take the form of in-
creased access to drugs for treatment and palliation, ex-
panded coverage for preventive and diagnostic services, as 
well as development and implementation of innovative 
health care delivery options to support rapid scale–up, 
while integrating access to patients in resource–poor re-
gions through national health insurance systems.
STRATEGIC APPROACH FOR CANCER 
CARE IN DEVELOPING SETTINGS
Provision of widespread and comprehensive cancer care is 
subject to criticisms that resemble those aimed at similar calls 
for control of HIV and MDR tuberculosis in previous years. 
In the case of HIV , some argued that antiretroviral treatment 
was too expensive to administer widely in the developing 
world, and that prevention, palliation, and less expensive 
treatments were the only justifiable and feasible options 
available [5]. In the cases of HIV and MDR tuberculosis, ini-
tially–expensive treatment became widely available when 
innovative treatment models and new investments were de-
veloped and implemented [6]. As a result of these efforts the 
number of HIV infected individuals receiving antiretroviral 
treatment increased more than 10-fold from 2003 to 2008, 
numbering, at the time, over 4 million [7].
Improving access to antiretroviral treatments for HIV pa-
tients models the fact that effective treatment for wide-
spread diseases can be administered in low– and 
middle–income countries. However, as with 
AIDS, prevention is as necessary as treatment. 
Neglecting prevention results in unaffordable 
and overwhelming treatment demands just as 
neglect of care results in unnecessary death and 
suffering. An approach that integrates prevention 
and treatment is necessary in any effort to con-
trol cancer in the developing world.
PROMISING INTERVENTIONS 
FOR CANCER CARE IN 
RESOURCE–POOR SETTINGS
While direct access to oncological surgery facili-
ties will remain a hurdle in low– and middle–in-
come countries, existing initiatives have shown 
that health systems can be implemented in a 
cost–effective manner [8,9]. The key to these sys-
tems’ success lies in establishing functional pri-
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Figure 1. Countries in the developing world bear the greatest 
burden of new cancer cases as well as deaths. By 2030, the 
developing world is expected to account for 70% of newly 
reported cancer cases [3].
Figure 2. Deaths due to cancer, HIV/AIDS, tuberculosis (TB), 
and malaria in the developing world. Cancer kills more people 
worldwide than HIV/AIDS, TB, and malaria combined [3].V
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mary care health infrastructures, particularly for cancers 
that are responsive to prevention and early detection ef-
forts, as well as cost–effective generic drugs. Opportunities 
to educate, diagnose, and provide surgery, therapeutics, 
and palliative care to cancer patients in low– and middle–
income countries should be identified and exploited. More-
over, an increase in the number of community health pro-
fessionals and facilities, as well as access to prevention and 
early detection, will represent substantial progress in the 
local health infrastructure which will ultimately translate 
into improved health outcomes. While a robust health in-
frastructure has a direct impact on health outcomes, it also 
works to alleviate economic hardship through job creation 
in local economies resulting from technology transfer, an 
emergent service industry based on mobilization and uti-
lization of health care professionals, and a host of other 
task–based positions that will emerge as a direct result of a 
functioning infrastructure [10]. Such an infrastructure, 
therefore, will serve to not only decrease mortality and 
morbidity due to the disease itself, but also effectively less-
en the poverty–related hardship that can lead to disease 
faced, in particular, by marginalized communities.
Along with building the local health infrastructure, the po-
tential of novel therapeutics needs to be exploited in devel-
oping settings. Nanotechnology is a multidisciplinary field, 
which includes a vast and diverse array of therapeutics de-
rived from chemistry, physics, engineering, and biomedi-
cine. Nanotechnology involves the manipulation of prop-
erties and structures at the nanoscale. Nanotechnology 
holds the promise of providing many significant benefits 
in medicine. For instance, Nanotechnology is being used 
for applications ranging from more effect drug delivery sys-
tems to highly sensitive pathogen detection platforms. To 
that end, the US National Institutes of Health has estab-
lished the National Cancer Institute Alliance for Nanotech-
nology in Cancer in order to dedicate concerted efforts and 
resources for the development of cancer diagnostics and 
therapeutics. Such applications of nanotechnology in the 
diagnosis and treatment of disease are collectively known 
as “nanomedicine” [11].
Conventional medicine is largely inaccessible to patients in 
the developing world because of its dependence on tech-
nology, laboratory facilities, and/or highly–trained medical 
professionals. Conversely, nanomedicine, based predomi-
nantly on prevention and early management of disease, by-
passes the need for scarcely–available, expensive labora-
tory equipment and medical expertise. Additionally, 
nanotherapeutics are fabricated in a highly–specific man-
ner at a nanoscale level using bottom–up molecular manu-
facturing methods, which makes these nanomedicine 
drugs easier to manufacture, distribute, and subsequently 
administer to patients, all of which translate into improved 
health outcomes in resource–limited settings [12].
Currently, nanotechnology–based medicine is considered 
not only a significantly promising path to accurate cancer 
diagnosis and effective treatment, but also a plausible way 
to prevent and manage several chronic diseases. As nano-
medicine evolves and becomes increasingly mainstream in 
clinical care, it is imperative to recognize its promise for 
combating the disproportionately high disease burden in 
the developing world. Applications of nanomedicine such 
as point–of–care diagnosis and effective nanoparticle–
based drugs and vaccinations have the potential to revolu-
tionize global health.
Part of the reason why low- and middle-in-
come countries lag behind wealthy nations in 
cancer survival rates is a lack of awareness, pre-
vention, and early detection, as well as inacces-
sibility of new and more effective treatments 
that have been developed in recent decades 
and made available to many in the first world.
SCALING–UP CANCER CARE IN THE 
DEVELOPING WORLD
We know that cancer is among the most pressing, and 
growing, global health challenges [13]. However, as the 
need for access to cancer care in low– and middle–income 
countries increases, the amount of resources devoted to the 
developing world remains stagnant. Indeed, a mere 5% of 
all resources devoted to cancer care globally are allotted to 
the developing world [14]. Considering the continually–
increasing number of individuals worldwide who will be 
diagnosed with cancer, lack of funding for care  (Figure 3) 
Figure 3. Funding (in US$) allocated to combat cancer, HIV/
AIDS, tuberculosis (TB), and malaria in the developing world. 
Funding for prevention and treatment of cancer amounts to 
approximately 2% of what is put towards other diseases [13].
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coupled with limited access to oncology physicians and 
treatment centers in low– and middle–income countries 
forecasts a global health disaster–in–waiting.
Many who have been diagnosed with cancer live and die 
in rural, resource–poor settings. Given the rising number 
of cancer cases worldwide, and the knowledge that a wide 
range of cost–effective measures exist to meet the global 
challenge of cancer, rapid and comprehensive scale–up of 
education, prevention, treatment, and palliation should be 
undertaken immediately. By implementing education, pre-
vention, and affordable treatment now, while simultane-
ously taking expeditious steps toward developing innova-
tive funding strategies for currently cost–restrictive care, 
global availability of cancer care can become a reality un-
bounded by income level or location.
CONCLUSIONS
In light of evidence that cancer prevention, diagnosis, treat-
ment, and palliation is feasible across low– and middle–in-
come countries, we call for the global health community to 
renew its efforts to make cancer drugs and other treatments 
affordable and accessible to all. We propose that cancer care 
and control be made available worldwide without delay, with 
particular attention paid to treating cancers that can be pre-
vented or cured, and palliating those that cannot.
We propose immediate implementation of the following: 
First, define and create new infrastructure, train health pro-
fessionals and paraprofessionals, and harness technology – 
especially telecommunications – to overcome geographic 
constraints, while identifying strategies that effectively alle-
viate the burden of cancer and expand health services in 
developing countries. Second, design and implement re-
gional and global pricing and procurement standards to of-
fer collective negotiation opportunities with an aim to re-
duce prices for essential services, drugs, and vaccines. 
Third, identify and implement innovative financing mecha-
nisms to expand financial resources available for prevention, 
treatment, and palliation of cancer in low– and middle–in-
come countries. Fourth, develop methods to support the 
creation of national policies surrounding cancer treatment 
to facilitate the implementation of the actions listed above.
Recalibrating global cancer care and control efforts could 
be transformative, but this kind of change will require a 
steadfast commitment to building integrated health infra-
structures in the most marginalized settings, developing 
novel therapeutics specifically for resource–limited set-
tings, and facilitating coordination between international 
organizations, bilateral donors, national research funding 
bodies, nongovernmental agencies, governments, and lo-
cal regional, and global civil society organizations in order 
to secure funding, maximize efficiency of implementation, 
and ultimately improve health outcomes. Extension of can-
cer prevention, diagnosis, and treatment to those suffering 
or at risk is an urgent global health concern. Bold research, 
financing, and implementation strategies are essential to fill 
the cancer care and control void between low–, middle–, 
and high–income countries, and should be undertaken in 
earnest without delay.
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